Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB4 | Q16877 | 10/20 | 0.60 |
| ▸ | PFKFB3 | Q16875 | 9/20 | 0.60 |
| ▸ | CMA1 | P23946 | 6/20 | 0.59 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3876651 | 0.90 | PFKFB4 (0.72) | PFKFB4PFKFB3CMA1F10 | |
| SCHEMBL3886516 | 0.89 | PFKFB3 (0.54) | PFKFB4PFKFB3CMA1 | |
| SCHEMBL3886517 | 0.86 | PFKFB3 (0.53) | PFKFB4PFKFB3CMA1 | |
| SCHEMBL3884692 | 0.83 | PFKFB3 (0.71) | PFKFB4PFKFB3CMA1F10 | |
| SCHEMBL3883767 | 0.79 | PFKFB4 (0.55) | PFKFB4PFKFB3CMA1F10 | |
| SCHEMBL3874736 | 0.79 | HSD11B1 (0.54) | PFKFB4PFKFB3CMA1F10 | |
| SCHEMBL3884734 | 0.79 | MAPT (0.51) | — | |
| SCHEMBL3874981 | 0.78 | PFKFB4 (0.51) | PFKFB4PFKFB3CMA1 | |
| SCHEMBL3874308 | 0.77 | PFKFB4 (0.45) | PFKFB4PFKFB3CMA1F10 | |
| SCHEMBL787869 | 0.75 | PFKFB3 (1.00) | PFKFB4PFKFB3CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814846-B1 | 11BETA-HSD1 INHIBITORS | EVOTEC AG (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-20090069323-A1 | 11beta-hsdi inhibitors | EVOTEC AG (DE) | 2009-03-12 | — | — | US | disclosed |
| EP-1814846-A1 | 11BETA-HSD1 INHIBITORS | Evotec AG (DE) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006048330-A1 | 11ΒΕΤΑ-HSD1 INHIBITORS | EVOTEC AG (DE) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069323-A1 | 11beta-hsdi inhibitors | HSD3B1, HSD3B2, HSD11B1 | PFKFB4 1312/4885PFKFB3 1134/4885CMA1 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.